Bookmarks

Observational Cohort Trial OCTAVE (OCTV)

Population Size

5,000

People

Population Size statistic card

Years

2023

Years statistic card

Associated BioSamples

None/not available

Associated BioSamples statistic card

Geographic coverage

United Kingdom

Geographic coverage statistic card

Lead time

2-6 months

Lead time statistic card

Summary

OCTAVE is a multi-disease, observational, cohort trial that will seek to understand the immune response to SARS-CoV-2 vaccinations in patients with certain immunosuppressed conditions.

Documentation

OCTAVE is a multi-disease, observational, cohort trial that will seek to understand the immune response to SARS-CoV-2 vaccinations in patients with certain immunosuppressed conditions.

Cohorts will include patients with chronic renal conditions, chronic liver conditions, inflammatory bowel disease, cancer (both solid and haematological malignancies), immune-mediated rheumatic/inflammatory conditions and haematopoietic stem cell transplant (HSCT) and chimeric antigen receptor (CAR) T recipients. OCTAVE is a collaborative research project involving academic partners from the Universities of Glasgow, Birmingham, Oxford, Imperial College London and the IMPACT network. The project is funded by the Medical Research Council, and badged as an Urgent Public Health trial supported by the NIHR Clinical Research Network.

Dataset type

Health and disease

Dataset sub-type

Not applicable

Dataset population size

5000

Associated media

https://www.youtube.com/watch?v=ZK9-Jw3uVkwhttps://www.hdruk.ac.uk/news/covid-19-vaccine-data-listed-and-available-to-request-through-hdr-innovation-gateway/?utm_source=hive&utm_medium=emailhttps://saildatabank.com/about-us/https://www.ukri.org/news/octave-study-shows-real-world-vaccine-response-in-at-risk-patients/

Keywords

Observations

Observed Node

Disambiguating Description

Measured Value

Measured Property

Observation Date

Persons

Patients with immunocompromised or immunosuppressed conditions.

5000

Count

28 Sep 2021

Provenance

Source of data extraction

Other

Collection source setting

Other, Secondary care - In-patients

Patient pathway description

Covid-19, Cohorts will include patients with chronic renal conditions, chronic liver conditions, inflammatory bowel disease, cancer (both solid and haematological malignancies), immune-mediated rheumatic/inflammatory conditions and haematopoietic stem cell transplant (HSCT) and chimeric antigen receptor (CAR) T recipients.

Image contrast

Not stated

Biological sample availability

None/not available

Structural Metadata

Details

Publishing frequency

Daily

Version

1.0.0

Modified

08/10/2024

Citation Requirements

Digital Health and Care Wales (DHCW)

Coverage

Start date

01/01/2023

Time lag

Less than 1 week

Geographic coverage

United Kingdom

Maximum age range

120

Follow-up

Other

Accessibility

Language

en

Controlled vocabulary

LOCAL

Format

SQL database table

Data Access Request

Dataset pipeline status

Available

Access rights

https://saildatabank.com/data/apply-to-work-with-the-data/

Time to dataset access

2-6 months

Access request cost

Data provision is free from SAIL. Overall project costing depends on the number of people that require access to the SAIL Gateway, the activities that SAIL needs to complete (e.g. loading non-standard datasets), data refreshes, analytical work required, disclosure control process, and special case technological requirements.

Access service description

The SAIL Databank is powered by the UK Secure e-Research Platform (UKSeRP). Following approval through safeguard processes, access to project-specific data within the secure environment is permitted using two-factor authentication.

Jurisdiction

GB-GBN

Data use limitation

Research-specific restrictions

Data use requirements

Project-specific restrictions,User-specific restriction

Data Controller

SAIL Databank

Data Processor

SAIL Databank

Dataset Types: Health and disease

Collection Sources: Other, Secondary care - In-patients

end of page